On Demand 2016 Food Allergy Package

Price: $109 members, $163 non-members

You can earn up to 8.75 AMA PRA Category 1 Credit(s)™. 

This package includes sessions from Food & Drug Allergy and GI Disorders category. 

  • The LEAP Study Results Should Be Applied to Foods Other Than Peanuts
  • W3 - Food Challenges in Practice: Safe and Simplified
  • Life and Diet for Infants After LEAP
  • The Great Raft Debate: The Best Treatment for Food Allergy Is…
  • W11 - Food Allergies: What's New in Prevention and Treatment?
  • W20 - Diagnostic Testing for Food Allergy: Old and New

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 8.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Recommend early feeding practices for infants at risk for development of food allergy
  • Recognize current evidence and knowledge gaps regarding primary prevention of food allergy
  • Describe how to perform an oral food challenge
  • Review indications for an oral food challenge and reasons for deferment
  • Identify which children are at highest risk of developing peanut allergy and of receiving the most benefit from early peanut introduction as a food allergy preventative strategy
  • Recommend means for facilitating safe introduction of peanut
  • Recommend strategies regarding the timing of introduction of other potential food allergens in the infant diet
  • Discuss the effectiveness of advising food avoidance and providing an anaphylaxis action plan
  • Describe new food allergy treatments that are likely to be FDA-approved in the next 5 years
  • Describe current primary prevention strategies and how additional primary prevention efforts may lead to a reduction in the prevalence of food allergy
  • Examine the current guidelines for the prevention of food allergy
  • Compare therapeutic strategies under investigation for food allergy
  • Select appropriate components to measure in patients with suspected food allergy, focusing on peanut
  • Recommend appropriate treatment based on the results of the component tests
Additional information
Disclosure: 

Trever Burnett, MD -- Speaker: Teva

Rima A. Rachid, MD -- Consultant/Advisor: Aimmune Therapeutics; Supported/Contracted Research: Aimmune Therapeutics

Hugh A. Sampson, MD, FACAAI -- Consultant/Advisor: Allertein, Danone Scientific Advisory Board, DBV Technologies, Herbs Spring, Thermo Fisher Scientific; Patent Holder/Royalty/IPR: Herbs Spring, LLC

Kirsten Beyer, MD -- Consultant/Advisor: ALK, Bausch & Lomb, Hycor, Meda, Nutricia; Speaker: Meda, Nutricia, Thermo Fisher Scientific; Supported/Contracted Research: DBV Technologies, Hycor, Nutricia

Richard W. Weber, MD, FACAAI -- Speaker: AstraZeneca, Meda, Merck; Supported/ Contracted Research: GlaxoSmithKline, Regeneron

David M. Fleischer, MD, FACAAI -- Consultant/Advisor: Nestle Nutrition Institute, Inc; Speaker: Nestle Nutrition Institute, Inc; Supported/ Contracted Research: DBV Technologies, Monsanto Company, Aimmune Therapeutics, Inc

Kirsten Beyer, MD -- Consultant/Advisor: ALK, Bausch & Lomb, Hycor, Meda, Nutricia; Speaker: Meda, Nutricia, Thermo Fisher Scientific; Supported/Contracted Research: DBV Technologies, Hycor, Nutricia

Matthew Greenhawt, MD, MSc, MBA, FACAAI -- Consultant/Advisor: Nutricia, Monsanto, Nestle, Aimmune, Adamis Pharmaceutical, Kaleo Pharmaceutical, Introimmune Pharmaceutical, Speaker: Thermo Fisher Scientific

Julie Wang, MD, FACAAI -- Consultant/Advisor: JDP Therapeutics, Aimmune; Supported/Contracted Research: JDP Therapeutics

The following have no financial relationships to disclose:

Amal H. Assa’ad, MD, FACAAI

Katrina Allen, MD, PhD

Sami L. Bahna, MD, DrPH, FACAAI

Kari C. Nadeau, MD, PhD

Maeve E. O’Connor, MD, FACAAI

Alkis Togias, MD, FACAAI

 

This activity is supported by independent educational grants from the following commercial supporters:

AstraZeneca Partial support of Workshop W24 on Managing Severe Asthma in Adults and Children.

Boston Scientific Supporter of the Virtual Roundtable on Advancing Management of Severe Asthma: A Review of Available Evidence to Guide Current Treatment.

CSL Behring Supporter of the Friday Symposium on Diagnosis and Treatment of Primary Immune Deficiency.

Dormer Laboratories Inc. In-kind support consisting of loaned durable equipment for Workshop W6 on Office Procedures for Allergic Skin Diseases.

GlaxoSmithKline Supporter of the Sunday Symposium on What to Do When Asthma Does Not Respond to Step 3 Treatment…and partial support of Workshop W24 on Managing Severe Asthma in Adults and Children.

Karl Storz Endoscopy-America, Inc. In-kind support consisting of loaned durable equipment for Workshops W12, W15 and W17 – Hands-On Session in Rhinolaryngoscopy.

Meda Pharmaceuticals, Inc. Supporter of the Monday Plenary Session on Asthma in 2016: Advances in Understanding Origin, Presentation and Approaches to Management.

Micro Direct, Inc. In-kind support consisting of loaned durable equipment for Workshops AHP3 and AHP6 Nuts and Bolts of Spirometry Interpretation.

Mylan Specialty L.P. Supporter of the Friday Breakfast Symposium on Leading the Pack: Allergists as Anaphylaxis Experts.

Nestlé Nutrition Institute Supporter of Workshop W11 on Food Allergies: What’s New in Prevention and Treatment.

Regeneron Pharmaceuticals/ Sanofi Genzyme Partial support of the Monday Plenary Session on Modern Therapies for Allergic Skin Diseases.

Salix Pharmaceuticals Partial support of the Friday Luncheon Symposium on Early Recognition and Effective Management of Hereditary Angioedema…and a video session of the symposium.

Shire Partial support of the Friday Luncheon Symposium on Early Recognition and Effective Management of Hereditary Angioedema…and the Sunday Symposium on Immunoglobulin Replacement for the Allergist: Update on Guidelines.

SmartPractice In-kind support consisting of loaned durable equipment for Workshop W6 on Office Procedures for Allergic Skin Diseases.

Teva Respiratory Supporter of the Friday Symposium on The Use of Biologics in Severe Asthma.

Course summary
Available credit: 
  • 8.75 AMA PRA Category 1 Credit™
  • 8.75 Attendance
  • 1.25 MOC
Course opens: 
12/01/2016
Course expires: 
11/30/2019
Cost:
$163.00
Rating: 
0

Available Credit

  • 8.75 AMA PRA Category 1 Credit™
  • 8.75 Attendance
  • 1.25 MOC

Price

Cost:
$163.00
Please login or create an account to take this course.